Litigation Details for Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc. (Fed. Cir. 2015)
✉ Email this page to a colleague
Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc. (Fed. Cir. 2015)
Docket | ⤷ Try a Trial | Date Filed | 2015-07-30 |
Court | Court of Appeals for the Federal Circuit | Date Terminated | |
Cause | Assigned To | ||
Jury Demand | Referred To | ||
Patents | 7,101,576 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc.
Details for Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc. (Fed. Cir. 2015)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2015-08-24 | 130639767 | Opening Brief for Appellants | that the asserted claims of U.S. Patent No. 7,101,576 (“’576 patent”), A60-94, are invalid as obvious…AGAIN BY FINDING THE PATENT INVALID FOR OBVIOUSNESS The ’576 patent is presumed valid. …DISTRICT COURT ERRED AGAIN BY FINDING THE PATENT INVALID FOR OBVIOUSNESS .......................…Cyclobenzaprine Hydrochloride Extended Release Capsule Patent Litigation), 676 F.3d 1063 (Fed. Cir. 2012) .…......................36 Talbert Fuel Systems Patents Co. v. Unocal Corp., 275 F.3d 1371 (Fed. Cir | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |